Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Endometrial Cancer | Research

Ninety-degree angled collimator: a dosimetric study related to dynamic intensity-modulated radiotherapy in patients with endometrial carcinoma

Authors: Alparslan Serarslan, Yalçın Daştan, Telat Aksu, Rana Elif Yıldız, Bilge Gürsel, Deniz Meydan, Nilgün Özbek Okumuş

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Our purpose was to ensure that the dose constraints of the organs at risk (OARs) were not exceeded while increasing the prescription dose to the planning target volume (PTV) from 45 to 50.4 Gray (Gy) with the dynamic intensity-modulated radiotherapy (IMRT) technique. While trying for this purpose, a new dynamic IMRT technique named 90° angled collimated dynamic IMRT (A-IMRT) planning was developed by us.

Methods

This study was based on the computed tomography data sets of 20 patients with postoperatively diagnosed International Federation of Gynecology and Obstetrics stage 2 endometrial carcinoma. For each patient, conventional dynamic IMRT (C-IMRT, collimator angle of 0° at all gantry angles), A-IMRT (collimator angle of 90° at gantry angles of 110°, 180°, 215°, and 285°), and volumetric modulated arc therapy (VMAT) were planned. Planning techniques were compared with parameters used to evaluate PTV and OARs via dose-volume-histogram analysis using the paired two-tailed Wilcoxon’s signed-rank test; p < 0.05 was considered indicative of statistical significance.

Results

All plans achieved adequate dose coverage for PTV. Although the technique with the lowest mean conformality index was A-IMRT (0.76 ± 0.05) compared to both C-IMRT (0.79 ± 0.04, p = 0.000) and VMAT (0.83 ± 0.03, p = 0.000), it protected the OARs especially the bladder (V45 = 32.84 ± 2.03 vs. 44.21 ± 6.67, p = 0.000), rectum (V30 = 56.18 ± 2.05 vs. 73.80 ± 4.75, p = 0.000) and both femoral heads (V30 for right = 12.19 ± 1.34 vs. 21.42 ± 4.03, p = 0.000 and V30 for left = 12.58 ± 1.48 vs. 21.35 ± 4.16, p = 0.000) better than C-IMRT. While the dose constraints of the bladder, rectum and bilateral femoral heads were not exceeded in any patient with A-IMRT or VMAT, they were exceeded in 19 (95%), 20 (100%) and 20 (100%) patients with C-IMRT, respectively.

Conclusions

OARs are better protected when external beam radiotherapy is applied to the pelvis at a dose of 50.4 Gy by turning the collimator angle to 90° at some gantry angles with the dynamic IMRT technique in the absence of VMAT.
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
2.
go back to reference Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterine neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:170–99.CrossRefPubMed Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterine neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:170–99.CrossRefPubMed
3.
go back to reference Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Arch. 2021;478:153–90.CrossRefPubMed Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Arch. 2021;478:153–90.CrossRefPubMed
4.
go back to reference Wang TJC, Wuu SC, Clifford Chao KS. Intensity modulated radiation treatment techniques and clinical applications. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Principles and practice of Radiation Oncology. Philadelphia: Wolters Kluwer; 2018. pp. 260–87. Wang TJC, Wuu SC, Clifford Chao KS. Intensity modulated radiation treatment techniques and clinical applications. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Principles and practice of Radiation Oncology. Philadelphia: Wolters Kluwer; 2018. pp. 260–87.
5.
go back to reference Macchia G, Deodato F, Cilla S, Cammelli S, Guido A, Ferioli M, et al. Volumetric modulated arc therapy for treatment of solid tumors: current insights. Onco Targets Ther. 2017;10:3755–72.CrossRefPubMedPubMedCentral Macchia G, Deodato F, Cilla S, Cammelli S, Guido A, Ferioli M, et al. Volumetric modulated arc therapy for treatment of solid tumors: current insights. Onco Targets Ther. 2017;10:3755–72.CrossRefPubMedPubMedCentral
6.
go back to reference Jhingran A, Winter K, Portelance L, Miller B, Salehpour M, Gaur R, et al. A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. Int J Radiat Oncol Biol Phys. 2012;84:e23–8.CrossRefPubMed Jhingran A, Winter K, Portelance L, Miller B, Salehpour M, Gaur R, et al. A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. Int J Radiat Oncol Biol Phys. 2012;84:e23–8.CrossRefPubMed
7.
go back to reference Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, et al. Patient-reported toxicity during pelvic intensity-modulated Radiation Therapy: NRG Oncology-RTOG 1203. J Clin Oncol. 2018;36:2538–44.CrossRefPubMedPubMedCentral Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, et al. Patient-reported toxicity during pelvic intensity-modulated Radiation Therapy: NRG Oncology-RTOG 1203. J Clin Oncol. 2018;36:2538–44.CrossRefPubMedPubMedCentral
8.
go back to reference Yang B, Zhu L, Cheng H, Li Q, Zhang Y, Zhao Y. Dosimetric comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy in patients with gynecologic malignancies: a systematic review and meta-analysis. Radiat Oncol. 2012;7:197.CrossRefPubMedPubMedCentral Yang B, Zhu L, Cheng H, Li Q, Zhang Y, Zhao Y. Dosimetric comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy in patients with gynecologic malignancies: a systematic review and meta-analysis. Radiat Oncol. 2012;7:197.CrossRefPubMedPubMedCentral
9.
go back to reference Onal C, Yuce Sari S, Yavas G, Oymak E, Birgi SD, Yigit E, et al. Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy. Acta Oncol. 2021;60:1154–60.CrossRefPubMed Onal C, Yuce Sari S, Yavas G, Oymak E, Birgi SD, Yigit E, et al. Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy. Acta Oncol. 2021;60:1154–60.CrossRefPubMed
10.
go back to reference Chargari C, Peignaux K, Escande A, Renard S, Lafond C, Petit A, et al. Radiotherapy for endometrial cancer. Cancer Radiother. 2022;26:309–14.CrossRefPubMed Chargari C, Peignaux K, Escande A, Renard S, Lafond C, Petit A, et al. Radiotherapy for endometrial cancer. Cancer Radiother. 2022;26:309–14.CrossRefPubMed
11.
go back to reference Chen JL, Huang YS, Huang CY, Hsu CY, Lan KH, Cheng WF, et al. Impact of adjuvant radiotherapy on the survival of women with optimally resected stage III endometrial cancer in the era of modern radiotherapy: a retrospective study. Radiat Oncol. 2020;15:72.CrossRefPubMedPubMedCentral Chen JL, Huang YS, Huang CY, Hsu CY, Lan KH, Cheng WF, et al. Impact of adjuvant radiotherapy on the survival of women with optimally resected stage III endometrial cancer in the era of modern radiotherapy: a retrospective study. Radiat Oncol. 2020;15:72.CrossRefPubMedPubMedCentral
12.
go back to reference Llewelyn M, Taylor A. Re-irradiation of cervical and endometrial cancer. Curr Opin Oncol. 2017;29:343–50.CrossRefPubMed Llewelyn M, Taylor A. Re-irradiation of cervical and endometrial cancer. Curr Opin Oncol. 2017;29:343–50.CrossRefPubMed
13.
go back to reference Deng X, Han C, Chen S, Xie C, Yi J, Zhou Y, et al. Dosimetric benefits of intensity-modulated radiotherapy and volumetric-modulated arc therapy in the treatment of postoperative cervical cancer patients. J Appl Clin Med Phys. 2017;18:25–31.PubMed Deng X, Han C, Chen S, Xie C, Yi J, Zhou Y, et al. Dosimetric benefits of intensity-modulated radiotherapy and volumetric-modulated arc therapy in the treatment of postoperative cervical cancer patients. J Appl Clin Med Phys. 2017;18:25–31.PubMed
14.
go back to reference Small W Jr, Bosch WR, Harkenrider MM, Strauss JB, Abu-Rustum N, Albuquerque KV, et al. NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target volume for Intensity modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: an update. Int J Radiat Oncol Biol Phys. 2021;109:413–24.CrossRefPubMed Small W Jr, Bosch WR, Harkenrider MM, Strauss JB, Abu-Rustum N, Albuquerque KV, et al. NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target volume for Intensity modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: an update. Int J Radiat Oncol Biol Phys. 2021;109:413–24.CrossRefPubMed
15.
go back to reference Mundt AJ, Yashar C, Mell LK. Endometrial Cancer. In: Lee NY, Lu JJ, editors. Target volume delineation and field setup. Berlin: Springer; 2013. pp. 187–93.CrossRef Mundt AJ, Yashar C, Mell LK. Endometrial Cancer. In: Lee NY, Lu JJ, editors. Target volume delineation and field setup. Berlin: Springer; 2013. pp. 187–93.CrossRef
16.
go back to reference Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1431–7.CrossRefPubMed Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1431–7.CrossRefPubMed
17.
go back to reference ICRU. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU Report 83. J ICRU. 2010;10:1–106.CrossRef ICRU. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU Report 83. J ICRU. 2010;10:1–106.CrossRef
18.
go back to reference Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, et al. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2013;86:83–90.CrossRefPubMedPubMedCentral Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, et al. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2013;86:83–90.CrossRefPubMedPubMedCentral
19.
go back to reference Yang R, Wang J, Xu S, Li H. SmartArc-based volumetric modulated arc therapy for endometrial cancer: a dosimetric comparison with helical tomotherapy and intensity-modulated radiation therapy. BMC Cancer. 2013;13:515.CrossRefPubMedPubMedCentral Yang R, Wang J, Xu S, Li H. SmartArc-based volumetric modulated arc therapy for endometrial cancer: a dosimetric comparison with helical tomotherapy and intensity-modulated radiation therapy. BMC Cancer. 2013;13:515.CrossRefPubMedPubMedCentral
20.
go back to reference Canturk E, Topgul G, Gurler O, Tunç S, Demiröz Abakay C, Kurt M, et al. Comparison of homogeneity indices for quantitative evaluation of dose homogeneity for ımrt treatments of endometrium, cervix and larynx cancers. J BAUN Inst Sci Technol. 2017;19:135–40. Canturk E, Topgul G, Gurler O, Tunç S, Demiröz Abakay C, Kurt M, et al. Comparison of homogeneity indices for quantitative evaluation of dose homogeneity for ımrt treatments of endometrium, cervix and larynx cancers. J BAUN Inst Sci Technol. 2017;19:135–40.
21.
go back to reference Chan P, Yeo I, Perkins G, Fyles A, Milosevic M. Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study. Radiat Oncol. 2006;1:13.CrossRefPubMedPubMedCentral Chan P, Yeo I, Perkins G, Fyles A, Milosevic M. Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study. Radiat Oncol. 2006;1:13.CrossRefPubMedPubMedCentral
22.
go back to reference Chan RJ, Webster J, Chung B, Marquart L, Ahmed M, Garantziotis S. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2014;14:53.CrossRefPubMedPubMedCentral Chan RJ, Webster J, Chung B, Marquart L, Ahmed M, Garantziotis S. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2014;14:53.CrossRefPubMedPubMedCentral
23.
go back to reference Foerster R, Schnetzke L, Bruckner T, Arians N, Rief H, Debus J, et al. Prognostic factors for long-term quality of life after adjuvant radiotherapy in women with endometrial cancer. Strahlenther Onkol. 2016;192:895–904.CrossRefPubMed Foerster R, Schnetzke L, Bruckner T, Arians N, Rief H, Debus J, et al. Prognostic factors for long-term quality of life after adjuvant radiotherapy in women with endometrial cancer. Strahlenther Onkol. 2016;192:895–904.CrossRefPubMed
24.
go back to reference Fernandes DCR, Andreyev HJN. Gastrointestinal toxicity of pelvic radiotherapy: are we letting women down? Clin Oncol (R Coll Radiol). 2021;33:591–601. Fernandes DCR, Andreyev HJN. Gastrointestinal toxicity of pelvic radiotherapy: are we letting women down? Clin Oncol (R Coll Radiol). 2021;33:591–601.
25.
go back to reference De Boer SM, Nout RA, Bosse T, Creutzberg CL. Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions. Expert Rev Anticancer Ther. 2019;19:51–60.CrossRefPubMed De Boer SM, Nout RA, Bosse T, Creutzberg CL. Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions. Expert Rev Anticancer Ther. 2019;19:51–60.CrossRefPubMed
26.
go back to reference Rodrigues ED, Gonsalves D, Teixeira L, López E. Frailty-the missing constraint in radiotherapy treatment planning for older adults. Aging Clin Exp Res. 2022;34:2295–304.CrossRefPubMed Rodrigues ED, Gonsalves D, Teixeira L, López E. Frailty-the missing constraint in radiotherapy treatment planning for older adults. Aging Clin Exp Res. 2022;34:2295–304.CrossRefPubMed
27.
go back to reference Huang J, Gu F, Ji T, Zhao J, Li G. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial. Radiat Oncol. 2020;15:180.CrossRefPubMedPubMedCentral Huang J, Gu F, Ji T, Zhao J, Li G. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial. Radiat Oncol. 2020;15:180.CrossRefPubMedPubMedCentral
28.
go back to reference Crombag MBS, Koolen SLW, Wijngaard S, Joerger M, Dorlo TPC, van Erp NP, et al. Does older age lead to higher risk for Neutropenia in Patients treated with Paclitaxel? Pharm Res. 2019;36:163.CrossRefPubMed Crombag MBS, Koolen SLW, Wijngaard S, Joerger M, Dorlo TPC, van Erp NP, et al. Does older age lead to higher risk for Neutropenia in Patients treated with Paclitaxel? Pharm Res. 2019;36:163.CrossRefPubMed
29.
go back to reference Gannavarapu BS, Hrycushko B, Jia X, Albuquerque K. Upfront radiotherapy with brachytherapy for medically inoperable and unresectable patients with high-risk endometrial cancer. Brachytherapy. 2020;19:139–45.CrossRefPubMed Gannavarapu BS, Hrycushko B, Jia X, Albuquerque K. Upfront radiotherapy with brachytherapy for medically inoperable and unresectable patients with high-risk endometrial cancer. Brachytherapy. 2020;19:139–45.CrossRefPubMed
30.
go back to reference Dörr W, Gabryś D. The principles and practice of re-irradiation in clinical oncology: an overview. Clin Oncol (R Coll Radiol). 2018;30:67–72.CrossRefPubMed Dörr W, Gabryś D. The principles and practice of re-irradiation in clinical oncology: an overview. Clin Oncol (R Coll Radiol). 2018;30:67–72.CrossRefPubMed
31.
go back to reference O’Hanlon S, O’Donovan A, Cree A. Geriatric oncology: assessing the needs of older people with cancer. Br J Hosp Med (Lond). 2019;80:252–57.CrossRefPubMed O’Hanlon S, O’Donovan A, Cree A. Geriatric oncology: assessing the needs of older people with cancer. Br J Hosp Med (Lond). 2019;80:252–57.CrossRefPubMed
32.
go back to reference Kadambi S, Loh KP, Dunne R, Magnuson A, Maggiore R, Zittel J, et al. Older adults with cancer and their caregivers - current landscape and future directions for clinical care. Nat Rev Clin Oncol. 2020;17:742–55.CrossRefPubMedPubMedCentral Kadambi S, Loh KP, Dunne R, Magnuson A, Maggiore R, Zittel J, et al. Older adults with cancer and their caregivers - current landscape and future directions for clinical care. Nat Rev Clin Oncol. 2020;17:742–55.CrossRefPubMedPubMedCentral
33.
go back to reference Barillot I, Tavernier E, Peignaux K, Williaume D, Nickers P, Leblanc-Onfroy M, et al. Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: results of the phase II RTCMIENDOMETRE French multicentre trial. Radiother Oncol. 2014;111:138–43.CrossRefPubMed Barillot I, Tavernier E, Peignaux K, Williaume D, Nickers P, Leblanc-Onfroy M, et al. Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: results of the phase II RTCMIENDOMETRE French multicentre trial. Radiother Oncol. 2014;111:138–43.CrossRefPubMed
34.
go back to reference Knapp P, Eva B, Reseigh G, Gibbs A, Sim L, Daly T, et al. The role of volumetric modulated arc therapy (VMAT) in gynaecological radiation therapy: a dosimetric comparison of intensity modulated radiation therapy versus VMAT. J Med Radiat Sci. 2019;66:44–53.CrossRefPubMed Knapp P, Eva B, Reseigh G, Gibbs A, Sim L, Daly T, et al. The role of volumetric modulated arc therapy (VMAT) in gynaecological radiation therapy: a dosimetric comparison of intensity modulated radiation therapy versus VMAT. J Med Radiat Sci. 2019;66:44–53.CrossRefPubMed
35.
go back to reference Sharma MK, Mitra S, Saxena U, Bhushan M, Shrivastava H, Simson DK, et al. Is volumetric modulated arc therapy (RapidArc) better than intensity modulated radiotherapy for gynecological malignancies? A dosimetric comparison. J Cancer Res Ther. 2014;10:883–8.CrossRefPubMed Sharma MK, Mitra S, Saxena U, Bhushan M, Shrivastava H, Simson DK, et al. Is volumetric modulated arc therapy (RapidArc) better than intensity modulated radiotherapy for gynecological malignancies? A dosimetric comparison. J Cancer Res Ther. 2014;10:883–8.CrossRefPubMed
Metadata
Title
Ninety-degree angled collimator: a dosimetric study related to dynamic intensity-modulated radiotherapy in patients with endometrial carcinoma
Authors
Alparslan Serarslan
Yalçın Daştan
Telat Aksu
Rana Elif Yıldız
Bilge Gürsel
Deniz Meydan
Nilgün Özbek Okumuş
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11033-8

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine